Treatment Of Obesity In Subjects Having Variant Nucleic Acid Molecules Encoding Calcitonin Receptor (CALCR)
AssigneeRegeneron Pharmaceuticals, Inc.
InventorsLuca Andrea Lotta, Parsa Akbari, Manuel Allen Revez Ferreira, Aris Baras
Life of this patent
Estimating the term…
Abstract
The present disclosure provides methods of treating subjects having obesity and/or increased body mass index (BMI), and methods of identifying subjects having an increased risk of developing obesity and/or BMI.
Claims63
A method of treating a subject with a therapeutic agent that treats or inhibits obesity and/or reduces body mass index (BMI), wherein the subject has obesity and/or increased BMI, the method comprising the steps of:
- determining whether the subject has a Calcitonin Receptor (CALCR) variant nucleic acid molecule encoding a CALCR predicted loss-of-function polypeptide by:
- obtaining or having obtained a biological sample from the subject;
- and
- performing or having performed a sequence analysis on the biological sample to determine if the subject has a genotype comprising the CALCR variant nucleic acid molecule;
- and
- administering or continuing to administer to the subject the therapeutic agent that treats or inhibits obesity and/or increased BMI in a standard dosage amount to a subject that is CALCR reference;
- or
- administering or continuing to administer to the subject the therapeutic agent that treats or inhibits obesity and/or increased BMI in an amount that is the same as or greater than a standard dosage amount to a subject that is heterozygous or homozygous for the CALCR variant nucleic acid molecule;
- wherein the presence of a genotype having the CALCR variant nucleic acid molecule encoding a CALCR predicted loss-of-function polypeptide indicates the subject has an increased risk of developing obesity and/or increased BMI.
A method of identifying a subject having an increased risk of developing obesity and/or increased body mass index (BMI), the method comprising:
- determining or having determined the presence or absence of a Calcitonin Receptor (CALCR) variant nucleic acid molecule encoding a CALCR predicted loss-of-function polypeptide in a biological sample obtained from the subject;
- wherein:
- when the subject is CALCR reference, the subject does not have an increased risk of developing obesity and/or increased BMI;
- and
- when the subject is heterozygous or homozygous for a CALCR variant nucleic acid molecule, then the subject has an increased risk of developing obesity and/or increased BMI.
A therapeutic agent that treats or inhibits obesity and/or increased body mass index (BMI) for use in the treatment of obesity and/or increased BMI in a subject having:
- a Calcitonin Receptor (CALCR) variant genomic nucleic acid molecule encoding a CALCR predicted loss-of-function polypeptide;
- a CALCR variant mRNA molecule encoding a CALCR predicted loss-of-function polypeptide;
- or
- a CALCR variant cDNA molecule encoding a CALCR predicted loss-of-function polypeptide.
Dependencies are inferred from the claim text.